Leading investigators in the area of HIV research from Johns Hopkins (JHU) and Makerere Universities (MU) propose to establish the Makerere University-Johns Hopkins University HIV Clinical Trials Unit-Kampala, Uganda to conduct critical HIV prevention and treatment research. This Clinical Trials Unit (CTU) consists of an administrative base at JHU and two Kampala clinical research sites (CRS). The MU-JHU Research Collaboration site will be affiliated with both the IMPAACT and the Microbicide Network applications, focusing on HIV prevention and treatment in women and children. The Infectious Diseases Institute site will be affiliated with the HPTN Network application with a focus on HIV prevention in adults. Both sites also have the capacity to expand to other network areas such as HIV vaccine end treatment studies. The clinical, data management, laboratory, and administrative resources and expertise necessary to screen, enroll, and retain HIV infected and uninfected participants in HIV prevention and treatment trials are currently available. The presence of the shared CAP-certified laboratory, community advisory boards, strong regulatory/QC sections, and local Ugandan IRB oversight coupled with extensive clinical trials experience will insure that all research is conducted to the highest scientific and ethical standards. The longstanding (>17 yr) relationship between JHU and MU investigators and support of the Uganda Ministry of Health has created a strong, productive, and mutually beneficial international center for HIV research that will be able to continue and expand through the funding of this application. Uganda has been at the forefront in HIV education, programs, and research in response to their devastating epidemic. However, rates of HIV infection in the 45,000 women in the Mulago hospital antenatal clinics yearly remain high (~11%), with transmission to neonates during pregnancy and breastfeeding. Women are economically and socially disadvantaged with limited capacity to protect themselves against infection. Access to HIV therapy is expanding, but lack of medical infrastructure and human capacity presents an ongoing challenge. Preventing HIV infection in adults and children and providing access to care to those infected is a worldwide public health crisis. The goal of this research unit is to find practical and affordable ways to accomplish this in a setting with limited resources. ADMINISTRATIVE COMPONENT:

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-MH-A (M1))
Program Officer
Welsch, Sue A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Mirembe, Brenda G; Kelly, Clifton W; Mgodi, Nyaradzo et al. (2016) Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. J Acquir Immune Defic Syndr 71:287-94
van der Straten, Ariane; Mayo, Ashley; Brown, Elizabeth R et al. (2015) Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial. AIDS Behav 19:770-83
Mgodi, Nyaradzo M; Kelly, Cliff; Gati, Brenda et al. (2015) Factors associated with bone mineral density in healthy African women. Arch Osteoporos 10:206
Herold, Betsy C; Dezzutti, Charlene S; Richardson, Barbra A et al. (2014) Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1. J Acquir Immune Defic Syndr 66:65-73
Kintu, Kenneth; Andrew, Philip; Musoke, Philippa et al. (2013) Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. J Acquir Immune Defic Syndr 63:1-8
Owor, Maxensia; Mwatha, Anthony; Donnell, Deborah et al. (2013) Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival. J Acquir Immune Defic Syndr 64:464-71
Kovalchik, Stephanie A (2012) Mother's CD4+ count moderates the risk associated with higher parity for late postnatal HIV-free survival of breastfed children: an individual patient data meta-analysis of randomized controlled trials. AIDS Behav 16:79-85
Onyango-Makumbi, Carolyne; Omer, Saad B; Mubiru, Michael et al. (2011) Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr 58:399-407
Onyango-Makumbi, Carolyne; Bagenda, Danstan; Mwatha, Antony et al. (2010) Early weaning of HIV-exposed uninfected infants and risk of serious gastroenteritis: Findings from two perinatal HIV prevention trials in Kampala, Uganda. J Acquir Immune Defic Syndr 53:20-7
Mmiro, Francis A; Aizire, Jim; Mwatha, Anthony K et al. (2009) Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda. J Acquir Immune Defic Syndr 52:32-9

Showing the most recent 10 out of 11 publications